- Details
- Brian Rini joins Pedro Barata to discuss the updated results of the Phase 3 LITESPARK-005 trial. The study, which led to belzutifan's approval in December 2023, compares belzutifan to everolimus in refractory clear cell RCC patients who previously received PD-1/PD-L1 and VEGF-TKI therapy. While the trial demonstrates improved progression-free survival and response rates with belzutifan, overall su...
|
- Details
- Leslie Ballas interviews Chad Tang about the use of stereotactic body radiation therapy (SBRT) in metastatic renal cell carcinoma (RCC). Dr. Tang discusses two key approaches: treating oligometastatic disease (up to five metastatic sites) and oligoprogressive disease (one to three progressing sites). He presents data from recent studies showing SBRT's potential to delay the need for systemic thera...
|
- Details
- Sam Chang interviews Ignacio Duran about the highlights of ESMO 2024 in non-prostate genitourinary oncology. Dr. Duran discusses key findings in kidney and bladder cancer. For kidney cancer, he highlights studies challenging the sequencing of checkpoint inhibitors and new treatment options for non-clear cell carcinoma. In bladder cancer, Dr. Duran reviews three studies that could impact clinical p...
|
- Details
- Alicia Morgans interviews David Braun about novel serum glycoproteomic biomarkers in the CheckMate 9ER study for kidney cancer. Dr. Braun discusses the exploratory post-hoc analysis using the InterVenn GlycoVision Glycoproteomics platform to investigate potential prognostic and predictive biomarkers. He highlights findings that higher levels of glycosylation are associated with worse outcomes, reg...
|
- Details
- Zachary Klaassen interviews Laurence Albiges about the CaboPoint Phase II Trial. Dr. Albiges discusses the evolving landscape of second-line treatment for clear cell renal cell carcinoma (RCC) after first-line immunotherapy combinations. The CaboPoint study evaluates cabozantinib as a pure second-line treatment in patients who have failed either nivolumab-ipilimumab or an IO-TKI strategy. Results...
|
- Details
- Chiara Ciccarese discusses the TACITO-II trial results, evaluating fecal microbiota transplantation (FMT) in patients receiving pembrolizumab plus axitinib for metastatic renal cell carcinoma. The phase II randomized study shows promising results, with FMT increasing the one-year progression-free survival rate from 35% to 66.7%. Dr. Ciccarese highlights the trial's novelty in demonstrating the tra...
|
- Details
- Eric Jonasch discusses data on NKT2152, a novel HIF-2 alpha inhibitor for clear cell renal cell carcinoma. The phase 1/2 study shows promising results in heavily pre-treated patients, with objective response rates around 25% and median progression-free survival of 7.4 months. Dr. Jonasch highlights the drug's efficacy across risk groups and its favorable safety profile, with anemia as the most com...
|
- Details
- Toni Choueiri discusses the TiNivo-2 trial results, comparing tivozanib-nivolumab combination to tivozanib monotherapy in advanced clear cell renal cell carcinoma. The study, involving 343 patients, shows no benefit in rechallenging with nivolumab after prior immunotherapy. Tivozanib monotherapy demonstrates efficacy, particularly in patients progressing directly from immunotherapy, with a progres...
|
- Details
- Lymphocytes are closely linked to mechanisms of action of immuno-oncology (IO) agents. We aimed to assess the prognostic significance of absolute lymphocyte count (ALC) in patients with metastatic renal cell carcinoma (mRCC). Biographies: Kosuke Takemura, MD, PhD, MPH, Staff Urologist, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan Related Content: Prognostic Sign...
|
- Details
- Pedro Barata interviews Yousef Zakharia about a phase 1/2 trial combining durvalumab and guadecitabine in metastatic kidney cancer. The study, conducted through the Big Ten Cancer Consortium, explores the potential synergy between hypomethylating agents and checkpoint inhibitors. Dr. Zakharia discusses the trial design, results, and biomarker findings. While the primary endpoint of objective respo...
|
